Drug Profile
Research Programme: antineoplastic monoclonal antibodies - Eisai Inc/John Wayne Cancer Institute
Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator John Wayne Cancer Institute; Morphotek
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung cancer; Malignant melanoma; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lung-cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)